AstraZeneca Expands Texas Manufacturing Facility
AstraZeneca has announced a $445 million expansion of its Coppell site to double production of Lokelma, a drug used to treat hyperkalemia.
The expansion will boost global production capacity, enhance local job growth, and strengthen the company's US manufacturing footprint.
- The Coppell plant is the only facility that produces Lokelma worldwide, shipping to over 50 countries.
- The expansion will add 9,000 square feet to the current facility, housing 250 employees.
- Two new manufacturing lines will be introduced, providing drug substance and drug product laboratory testing, warehousing, and administrative space.
Lokelma—sodium zirconium cyclosilicate—is used to treat hyperkalemia, high potassium levels in the blood.
AstraZeneca's expansion is part of industry-wide onshoring trends, aiming to increase local production and reduce reliance on external suppliers.
Author's summary: AstraZeneca invests $445 million to expand Texas facility.
More News
- CFL Scores Today: BC Lions 37, Edmonton Elks 24 – Lions Roar Back for Fifth Straight Win
- Dan's Daily: Jagr Back; Team USA Makes Demands; Penguins Changes
- Texas faces heightened wildfire threat amid ongoing drought
- Chelsea enjoy thumping win at Forest - West London Sport
- Chelsea enjoy thumping win at Forest - West London Sport
- The 5 Biggest State Tax Cuts for Millionaires this Year
- Chiefs Chapel is changing what Sunday means for fans at Arrowhead